2025/04/04

The Scientific Advisory Board visits CIC bioGUNE in its commitment to excellence and scientific advancement

This week , CIC bioGUNE, member of BRTA, hosted the visit from its Scientific Advisory Board (SAB), comprised of internationally recognized scientists in disciplines such as oncology, neuropathology, biochemistry, molecular biology, and chemistry. During their visit, SAB members met with the center's research staff to gain firsthand insight into the scientific progress made in recent years.

The CIC bioGUNE’s SAB convenes every three years at the center's headquarters and is composed of the following distinguished scientists:

• Adriano Aguzzi, Institute of Neuropathology, University Hospital of Zurich, Switzerland.
• Quentin M. Anstee, Institute of Cellular Medicine, Newcastle University, United Kingdom.
• Cathrin Brisken, ISREC, School of Life Sciences, and Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland.
• Tom Blundell, Department of Biochemistry, University of Cambridge, United Kingdom.
• Christian Griesinger, Max Planck Institute for Biophysical Chemistry, Germany.
• Mª José Alonso, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Spain.
• Ulrich Günther, University of Lübeck – Institute of Chemistry and Metabolomics, Germany.
• Richard Henderson, Nobel Laureate in Chemistry – MRC Laboratory of Molecular Biology, United Kingdom.
• Caroline Dive, Cancer Research UK – President of the European Association for Cancer Research (EACR).
• Marisol Soengas, Spanish National Cancer Research Center (CNIO), Spain.
• Anne Imberty, Research Center for Plant Macromolecules (CERMAV), Grenoble, France.

During the sessions, the most recent research projects were presented and discussed. The primary function of the Scientific Advisory Board is to harness collective expertise to inform decision-making processes, promote scientific development, and ensure that scientific evidence is effectively integrated into the center’s strategies and objectives. This interaction reinforces CIC bioGUNE’s commitment to scientific excellence and international collaboration.

CIC bioGUNE is distinguished by its ability to approach research from a multidisciplinary perspective, integrating fields such as chemistry, biology, biomedicine, and mathematics to develop new tools and methodologies for cancer treatment. The center is actively engaged in generating foundational knowledge and exploring new technologies that, over time, could lead to clinical, diagnostic, and therapeutic applications.

CIC bioGUNE would like to extend its sincere appreciation to the members of the Scientific Advisory Board for their continued commitment and contributions to the strategic development of the center. Their knowledge and experience are fundamental to advancing scientific excellence and biomedical innovation.

About CIC bioGUNE
The Centre for Cooperative Research in Biosciences (CIC bioGUNE), member of the Basque Research & Technology Alliance (BRTA), located in the Bizkaia Technology Park, is a biomedical research organization conducting cutting-edge research at the interface between structural, chemical, molecular and cell biology, with a particular focus on generating knowledge on the molecular bases of disease, for use in the development of new diagnostic methods and advanced therapies.

About BRTA
BRTA is an alliance of 4 collaborative research centres (CIC bioGUNE, CIC nanoGUNE, CIC biomaGUNE y CIC energiGUNE) and 13 technology centres (Azterlan, Azti, Ceit, Cidetec, Gaiker, Ideko, Ikerlan, Leartiker, Lortek, Neiker, Tecnalia, Tekniker y Vicomtech) with the main objective of developing advanced technological solutions for the Basque corporate fabric.

With the support of the Basque Government, the SPRI Group and the Provincial Councils of the three territories, the alliance seeks to promote collaboration between the research centres, strengthen the conditions to generate and transfer knowledge to companies, contributing to their competitiveness and outspreading the Basque scientific-technological capacity abroad.

BRTA has a workforce of over 4,000 professionals, executes 22% of the Basque Country's R&D investment, registers an annual turnover of more than 300 million euros and generates 100 European and international patents per year.

Spanish version